4588 — Oncolys Biopharma Balance Sheet
0.000.00%
Last trade - 00:00
- ¥14bn
- ¥13bn
- ¥63m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 3,343 | 2,068 | 3,455 | 1,711 | 1,533 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 217 | 168 | 377 | 318 | 102 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 3,826 | 2,546 | 4,198 | 2,609 | 1,956 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 11.8 | 21.3 | 0 | 0 | 0 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 4,380 | 2,796 | 4,292 | 2,651 | 2,041 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 524 | 415 | 430 | 322 | 379 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 926 | 793 | 698 | 492 | 567 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 3,454 | 2,003 | 3,594 | 2,159 | 1,474 |
Total Liabilities & Shareholders' Equity | 4,380 | 2,796 | 4,292 | 2,651 | 2,041 |
Total Common Shares Outstanding |